



### 2022 - 2025 Strategic Plan

27 February 2023

### Disclosure



This document has been prepared by Antares Vision S.p.A for use during meetings with investors and financial analysts and is solely for information purposes. The information set out here in has not been verified by an independent audit company.

Neither the Company nor any of its subsidiaries, affiliates, branches, representative offices (the "Group"), as well as any of their directors, officers, employees, advisers or agents (the "Group Representatives") accepts any responsibility for/or makes any representation or warranty, express or implied, as to the accuracy, timeliness or completeness of the information set out herein or any other related information regarding the Group, whether written, oral or in visual or electronic form, transmitted or made available.


This document may contain forward-looking statements about the Company and/or the Group based on current expectations and opinions developed by the Company, as well as based on current plans, estimates, projections and projects of the Group. These forward-looking statements are subject to significant risks and uncertainties (many of which are outside the control of the Company and/or the Group) which could cause a material difference between forward-looking information and actual future results.

The information set out in this document is provided as of the date indicated here in. Except as required by applicable laws and regulations, the Company assumes no obligation to provide updates of any of the aforesaid forward-looking statements.

Under no circumstances shall the Group and/or any of the Group Representatives be held liable (for negligence or otherwise) for any loss or damage howsoever arising from any use of this document or its contents or otherwise in connection with the document or the aforesaid forward-looking statements. This document does not constitute an offer to sell or a solicitation to buy or subscribe to Company shares and neither this entire document or a portion of it may constitute a recommendation to affect any transaction or to conclude any legal act of any kind whatsoever.

This document may not be reproduced or distributed, in whole or in part, by any person other than the Company. By viewing and/or accepting a copy of this document, you agree to be bound by the foregoing limitations.





### **AGENDA**


Section 1 – Market Outlook

Section 2 – Strategy Implementation Plan

Section 3 – Financial Targets

#### OUR MARKETS TODAY: LARGE, RESILIENT AND GROWING






Sources: Euromonitor International Ltd, Passport Data Extracted October 2022 Notes

- 1. Pharmaceutical Production (Turnover MSP), y-o-y exchange rates, current prices
- 2. Medical and Surgical Equipment Production (Turnover MSP), ), y-o-y exchange rates, current prices as per "Medical Devices" definition
- 3. Food Production (Turnover MSP), y-o-y exchange rates, current prices,
- 4. Beverages Production (Turnover MSP), y-o-y exchange rates, current prices
- 5. Home Care (retail value MSP), y-o-y exchange rates, current prices

- 6. Beauty and Personal Care (retail value MSP), y-o-y exchange rates, current prices, as per "Personal Care" definition,
- 7. GDP, YoY exchange rates, current prices
- 9. 2027 market value calculated with 21-26 CAGR
- 8. Calculated as weighted average of the following industries in the reference periods: Pharmaceutical Production (Turnover MSP); Medical and Surgical Equipment Production (Turnover MSP), as per "Medical Devices" definition; Food Production (Turnover MSP); Beverages Production (Turnover MSP); Home Care (retail value MSP); Beauty and Personal Care (retail value MSP), as per "Personal Care" definition


# AT THE NEXUS OF A STRUCTURAL SHIFT TOWARDS SUPPLY CHAIN DIGITALIZATION, SUSTAINABILITY AND TRUSTPARENCY ©





#### LARGE, FAST GROWING AND UNTAPPED TOTAL ADDRESSABLE MARKET





#### IN 2027 ANTARES VISION GROUP TOTAL ADDRESSABLE MARKET (\$25.3Bn) WILL BE 6x VS TODAY (\$4Bn)

Sources: Markets & Markets, UCIMA (MECS - Centro Studi Ucima), Qualiket Research

<sup>1.</sup> Elaboration on data from Markets & Markets (T&T), UCIMA (Inspection), Qualiket Research (Smart Data)


<sup>2.</sup> Due to rounding, the sum of the different numbers could slightly differ from the total 3. Original market value of €2.1 Bn, converted at average 2021 €/\$ exchange ratio, source BCE


<sup>4.</sup> Includes other consumer and industrial T&T markets such as chemicals, components, raw materials, jewellery, transport & logistics and other

# REGULATION PAVING THE WAY FOR ALL-TIME HIGH T&T PENETRATION IN PHARMACEUTICALS



Rapid evolution ahead of us, with industrial market continuing to develope





### INDUSTRIAL MARKET IS LARGE, STILL IN DEVELOPING PHASE AND YEARS BEHIND PHARMACEUTICALS



On-going trends: traceability beyond pharmaceuticals

#### COUNTRIES WITH DEVELOPED PHARMA REGULATIONS TEND TO EXPAND TRACK & TRACE REGULATIONS TO OTHER INDUSTRIES

- Turkey: Pilot country for pharmaceutical serialization beginning 2010
- China: introduced a law for Food & Beverage T&T in the program Made in China 2025
- USA: the FDA New Era of Smarter Food Safety (2020-2030) for safer and more digital traceable food system and FSMA 204, for additional traceability requirements for certain foods
- EU: Animal Health regulation on veterinary products identification began January 2022
- India: API Traceability, 300 domestic brands and export drugs since January 2023
- APAC/GMS: Agri-Food Traceability cross- borders project
- Canada/Australia: Pharma and medical devices traceability
- MEA: Bahrain, Qatar, Jordan, Lebanon, Oman Traceability per GS1 standards
- AFRICA: Nigeria and other countries are starting to publish Full T&T regulations for pharm and retail
- LATAM: Other countries developing regulations despite of Brazil and Ecuador putting theirs on hold




Sources: Management Elaboration on GS1 Data


Notes:

1. Expected year of enforcement

#### TRACK & TRACE: GROWTH BY END-MARKETS AND GEOGRAPHIES









✓ APAC – addressed also by smaller local T&T solutions manufacturers – gaining market share, mostly at the expense of Europe




- ✓ APAC and North America expected to be the fastest growing markets
- North America to dominate track and trace solutions market during forecast period
- ✓ Europe expected to maintain its leading position

FORMAL ADOPTION OF SERIALIZATION AND AGGREGATION REGULATION IN MANY MARKETS IS EXPECTED TO DRIVE SIGNIFICANT GROWTH

#### INSPECTION MARKET: MARKET BREAKDOWN BY END-MARKET







- ✓ Inspection market more concentrated by end-market
- ✓ Life Science and Food & Beverage core end-markets for Antares Vision Group – represent the two main segments



✓ Life Science and Food & Beverage growth driven by the need to comply with strict industry quality standards and focus on end-to-end visibility and transparency

Sources: UCIMA (MECS - Centro Studi Ucima)


otes

Original market value converted at average 2021 €/\$ exchange ratio, source BCE
 Includes Cosmetics, Chemicals, Tobacco, Tissue, Building materials and other

#### INSPECTION: LARGE AND ROBUST MARKET BOTH IN LIFE SCIENCE AND F&B



#### LIFE SCIENCE INSPECTION BY GEOGRAPHY Bn € (1) , ,\_\_\\_\_\\_\_, **CAGR** \$1.1 Bn (1) \$1.2 Bn (1) \$1.0 Bn (1) '19A-21A '21A-27E -0.8% +0.2% 1.0 1.0 1.0 0.1 0.1 RoW -3.4% 1.4% 0.1 0.1 0.1 0.1 North 14.8% 0.2% America 0.4 0.4 -2.1% 0.4 **APAC** 1.4% 0.4 0.4 -3.0% -1.3% 0.3 Europe 2021 2027 2019





- ✓ Life Science inspection is forecasted to be a **flat market**
- ✓ Europe and APAC represent the main markets



√ F&B Inspection is forecasted as slowing growing market, with a 1.4% CAGR 2021-25


Sources: UCIMA (MECS - Centro Studi Ucima)

Notes

<sup>1.</sup> Original market value converted at average 2021 €/\$ exchange ratio, source BCE

#### SMART DATA: SUMMARY OVERVIEW OF MARKET DYNAMICS






GROWTH DRIVEN BY INCREASING RECOGNIZED ADVANTAGES FROM SMART DATA APPLICATION AND POTENTIAL FROM INTEGRATION WITH ARTIFICIAL INTELLIGENCE


#### SMART DATA: GROWTH BY END-MARKETS AND GEOGRAPHIES



#### SMART DATA MANAGEMENT BY END-MARKET



#### SMART DATA MANAGEMENT BY GEOGRAPHIES





- ✓ Market led by pharmaceuticals and medical devices with expansion to other businesses by 2027E
- ✓ Smart Data Management at the focal point of a digital supply chain



✓ Developed markets (North America and Europe) historically the main markets, with North America expected to dominate the market by 2025E driven by the largest adoption of smart data technologies

# ANTARES VISION OFFERS THE MOST INTEGRATED SOLUTION WITH WIDEST COVERAGE OF END-MARKETS OVER THE ENTIRE LIFE CYCLE



	TRACK & TRACE				INSPE	CTION	SMART	DATA	
	STANDALONE MACHINE	INTEGRATION KIT	PLANT SOFTWARE	CORPORATE SOFTWARE	MACHINE	SYSTEMS	MANUFACTURING 4.0	SUPPLY CHAIN	Н
ANTARES VISION GROUP	✓	✓	✓	✓	✓	✓	✓	✓	
Player 2	✓	✓	✓	✓		✓		✓	
Player 3			✓		✓		✓		
Player 4	✓	✓	✓	✓				✓	
Player 5	✓	✓	✓			✓			
Player 6					✓				
Player 7		✓	✓			✓	✓		
Player 8					✓				
Player 9	✓	✓			✓				
Player 10	✓	✓	✓	✓		✓			
Player 11				✓				✓	
Player 12					✓	✓			

#### KEY MARKET TAKEAWAYS



Large, fast-growing and untapped total addressable market, with significant opportunities



Attractive end-markets driven by:

- ✓ Increasing regulatory requirements
- ✓ Accelerating emphasis on sustainability
- √ Health and safety importance
- √ Focus on digitalizing the supply chain
- ✓ End-to-end visibility and transparency




- ✓ Robust track record
- √ Number of growth levers
- ✓ Core markets remain underpenetrated



- Number of new markets undergoing a structural shift towards more digitalized, transparent and sustainable supply chains
- Antares Vision Group is ideally positioned to capture the growth potential from this secular transition towards digital and sustainable supply chains





### **AGENDA**

Section 1 – Market Outlook

Section 2 – Strategy Implementation Plan

Section 3 – Financial Targets

# WELL DEFINED STRATEGY PILLARS SETTING THE GROUND FOR FUTURE GROWTH




#### **GROWTH DRIVERS**

- 1 UNTAP ANTARES VISION PLATFORM CROSS-SELLING FULL POTENTIAL
- FURTHER PENETRATION AND CONSOLIDATION INTO LIFE SCIENCES AND F&B MARKETS
- 3 EXPANSION TO ADJACENT MARKETS
- PROGRESSIVE SHIFT TOWARDS A RECURRING REVENUE MODEL
- 5 CLEAR M&A STRATEGY TO STRENGHTEN AV PLATFORM ACROSS TECHNOLOGIES, MARKETS AND GEOGRAPHIES

**KEY ENABLERS** 





NEW ORGANISATIONAL SETUP AND INVESTMENTS INTO TALENTS TO SUPPORT THE STRATEGY



IMPLEMENTATION OF BEST PRACTICES TO ALLOW FURTHER EFFICIENCIES AND UNLOCK MARGIN EXPANSION

#### LIFE SCIENCE AND FMCG CROSS-SELLING OPPORTUNITIES




In Life Science business area, consistent cross-selling opportunities are expected between existing product lines <sup>1</sup>

a, ies <sup>1</sup>

Total


accounts

2022
CROSS-SELLING ACROSS DIFFERENT PUs<sup>3</sup> IN
LIFE SCIENCE




MID-TERM TARGETS

CROSS-SELLING ACROSS DIFFERENT PUs<sup>3</sup> IN LIFE SCIENCE




In FMCG, the evolution of cross-selling opportunities projections are driven mainly by key accounts <sup>2</sup>





CROSS-SELLING ACROSS DIFFERENT PUs<sup>3</sup> IN **FMCG** 



- 1\* % of clients generating revenues for more than one product unit over clients generating revenues from T&T
- 2\* % of clients generating revenues for more than one product unit over clients generating revenues from Inspection
- 3\* Product Units

18

### FURTHER PENETRATION AND CONSOLIDATION INTO LIFE SCIENCE




		Key strategic guidelines	T&T	INSP.	SD
	ADDRESSING COMPETITOR'S CUSTOMERS TO GAIN NEW CLIENTS	<ul> <li>Gain new clients that are currently served by competitors</li> </ul>	✓	<b>√</b>	<b>√</b>
	SWITCH TO AGGREGATION	<ul> <li>Push products to address the need of Aggregation in the Supply Chain in US (2023 regulation) and EU (market practice)</li> </ul>	$\checkmark$		
CURRENT CORE MARKETS (EUROPE, US)	EXTEND COVERAGE ON EXISTING CLIENTS	<ul> <li>Extend the number of installed lines for existing customers</li> </ul>	<b>√</b>	<b>√</b>	<b>√</b>
	NEW CUSTOMERS IN INSPECTION (MARKET PENETRATION)	Further increase the penetration of inspection market		<b>√</b>	
	ADDRESS NEW CLIENTS ON INTEGRATED SOLUTIONS TENDER	<ul> <li>Develop our ecosystem to offer a one stop-one shop experience</li> </ul>	$\checkmark$	<b>√</b>	<b>√</b>
EXPANSION MARKETS	REINFORCE INSPECTION WHILE PREPARING FOR T&T	<ul> <li>Push inspection sales in China, APAC, India, Brasil to gain accounts and consolidate positions (T&amp;T regulations expected in the future)</li> </ul>		<b>√</b>	

© 2023 Antares Vision

### FURTHER PENETRATION AND CONSOLIDATION INTO F&B MARKET





### PENETRATION IN ADJACENT MARKETS – KEY GUIDELINES



#### **Key strategic guidelines**

**COSMETICS & FRAGRANCES** 

 Expand into the Cosmetics market and build a strong track-record to become the Solutions Provider that defines the standards

FASHION & LUXURY

Enter the Fashion & Luxury market to unlock a new highpotential end market

**CHEMICALS** 

 Extend the market development on Chemical Market (Current/New products, new markets): extend presence on Chemical markets (Home care & Personal Care, Mineral Oil, Chemical Industry) to promote the entire portfolio of Antares Vision Group


FOOD &
BEVERAGE
(SUPPLY CHAIN
TRANSPARENCY)

 Development of innovative solution on supply chain transparency from raw material to consumer on Food & Beverage



# EXPANSION STRATEGY RELIES ON A STRONG GROWTH, PROGRESSIVELY SHIFTING TOWARDS A RECURRING REVENUE MODEL







# THE NEXT-GEN: AN INTEGRATED ECOSYSTEM AND AN EVOLUTION OF THE BUSINESS MODEL

mi



# **Platform**

**Plant** 

#### **LEVEL 5 – Regulatory**



- Serves as the regulatory repository
- Authoritative source of regulated serial numbers

#### **LEVEL 4 - Corporate**

- Ensures compliance reporting & traceability
- Generates & manages serial numbers for L2/L3
- Verifies the integrity of submitted data

#### LEVEL 3 – Site

- Serial generation & data repository (site)
- Recipes management/storage
- Line data dispatching/Production planning

#### **LEVEL 2 - Line**

- Line manager/Work order management
- Real time serialization
- Production data statistics

#### LEVEL 1 - Devices

- Devices on packaging line: barcode printers, labelers, cameras, scanners, etc.
- Serialization modules/integration



. . . .

W→

#### SUPPLY CHAIN TRANSPARENCY

Digitalization for data-driven approach, Business Intelligence




Next-gen unique **end-to-end ecosystem** that **connects physical with digital**, from the raw materials to the end user, enabling a **deep smart product and supply chain transparency** 

#### INTEGRATION ENABLERS

- Cross selling leveraging the existing customer base
- One Step Ahead for our customers and potential
- ✓ New opportunities of business
- ✓ Service Support Development
- ✓ New business model as a service

#### **BUSINESS MODEL EVOLUTION**



© 2023 Antares Vision



# IMPLEMENTATION OF BEST PRACTICES AND REVENUE MODEL SHIFT TO ALLOW FURTHER EFFICIENCIES AND UNLOCK PROFITABILITY



#### **REVENUE SHIFT & COGS IMPROVEMENT**



INCREASING RECURRING REVENUES, ESPECIALLY SOFTWARE



**SUPPLY CHAIN RATIONALIZATION** 



**DESIGN EFFICIENCIES** 



INSTALLATION PROCESS STANDARDIZATION

#### STREAMLINED STRUCTURE & OUTSOURCING



PRODUCT & PROCESSES OPTIMIZATION



REDUCTION OF **INSTALLATION TIMES** 



GROUP STRUCTURE STREAMLINING

#### **OPERATING LEVERAGE**



**ECONOMIES OF SCALE** & INVESTMENTS




MORE **EFFICIENT USE OF EXT. RESOURCES** 



SYNERGIES ON MARKETING COSTS





### **AGENDA**

Section 1 – Market Outlook

Section 2 – Strategy Implementation Plan

Section 3 – Financial Targets

### 2022 – 2025 FINANCIAL TARGETS (EXCLUDING M&A)



	<b>2022PC</b> <sup>1</sup>	2025E		
Total Group Revenues	€ 224 M	2022-25 CAGR 12% - 14% 2023 GUIDANCE €250-260 M		
ADJ. EBITDA Margin %	~18%	25% - 27%		
Capex	~ € 21M²	2023-25 CAPEX ~ € 60 M		
Financial Position	NET DEBT~ €63M <sup>3</sup>	NET CASH ~ € 60-70 M		

**Sources:** Company Information

Notes:

3. Net of warrant


<sup>1.</sup> Pre-Closing

<sup>2.</sup>Excluding €2.6m minority investments and €3.4m related to IFR 16

# AV GROUP IS EXPECTED TO REACH A BALANCED MIX, STRENGTHING IN FMCG WHILE MAINTAINING A ROBUST GROWTH IN THE LIFE SCIENCE SECTOR




Sales growth evolution by end-market, 2022PC (€M)



# BETWEEN 22 AND 25, SMART DATA WILL GROW WITH THE HIGHEST CAGR, INCREASING ITS RELATIVE WEIGHT




Sales growth evolution by technological solutions, 2022PC (€M)



# SOFTWARE AND SERVICE ARE THE MOST DYNAMIC SEGMENTS, COVERING >50% OF '22-'25 GROWTH




Sales growth evolution by technology, 2022PC - 2025E (€M)



# AV GROUP'S BACKLOG IS GROWING THANKS TO RECURRING REVENUES AND TO THE COMMERCIAL PUSH ON EXISTING SEGMENTS



Total backlog - 2022A and 2023A, M€



# THE BEGINNING-OF-YEAR BACKLOG COVERAGE OVER YEARLY SALES IS IMPROVING BETWEEN 2021A AND 2023A, REACHING 60-63% FOR 2023




#### **Backlog Coverage KPI**

2021A<sup>1</sup>, 2022A<sup>2</sup> and 2023A, M€ and %

#### Calculation method

The backlog coverage (%) is calculated as delivered sales from Beginning of Year backlog / yearly sales




Assumptions

- In 2023, for FMCG, the backlogs of Inspection, Service and T&T are assumed to be delivered at 100%, while the Ratio of other technological solutions is assumed to be equal to the average between 2021 and 2022
- rfxcel backlog in 2021 is assumed to be delivered at the same rate of 2022
- If backlog is higher than yearly sales, a coverage % of 100% is assumed

Source: Company Information


Does not include ACSIS
 Includes ACSIS and rfxcel





### Q & A SESSION







# THE DIVERSIFIED REVENUE MODEL INCLUDES DIFFERENT REVENUE TYPES AND DRIVERS CORRESPONDING TO THE COMPANY'S PRODUCT UNITS



#### Antares Vision Group revenue model

SOLUTION	BUSINESS MODEL	SALES TERMS	TYPE OF REVENUE	REVENUE DRIVERS
TRACK AND TRACE	Lines installed (T&T equipment)	Sales contract	First installation	Avg. price per line
			First installation	Number of installed lines
	Services and after-sales Support (maintenance + spare parts)	Subscription contracts (3Y on avg with possible annual price renegotiation)     One-off maintenance interventions	Recurring / 1-off	Avg. subscription price
				Installed base <sup>1</sup>
INSPECTION	Systems / machines installed (Inspection machines)	Sales contract	First installation	Avg. price per system / machine
				Number of installed systems / machines
	Services and after-sales	<ul><li>Subscription contracts</li><li>One-off maintenance interventions</li></ul>	Recurring / 1-off	Avg. subscription price
	support (maintenance + spare parts)			Installed base <sup>1</sup>
SMART DATA	Smart Data / Digital Factory	Tompovory sub-scription contract	Recurring	Avg. price per license
	Smart Data / Digital Factory	Temporary subscription contract	Recuiring	Number of issued licenses
	SaaS (Includes L4 software)	Installation + multi-year subscription contract (5-6Y on avg)	Recurring	One-off Implement fee + periodic fee (variable on managed serial #s volume threshold)

Source: Company Information

Notes

2. The price may depend on the type/quantity of processing and the number of users/licence

<sup>1.</sup> Revenues from line services are assumed to start with 1 year delay from installation timing





### Alessandro Baj Badino

Head of Investor Relations

+39 335 122 30 89

Alessandro.bajbadino@antaresvision.com

#### Davide Antonioli

Investor Relator

+39 339 812 44 46

Davide.antonioli@antaresvision.com